Progress in prediction and prevention of SCD, and reducing its public health burden, is dependent upon methods for risk prediction that will identify small pockets of high risk currently concealed within the general and low-risk clinical populations. 5 The challenge is transitioning from a focus on population risk to being able to model individual risk more accurately. This will not come easily, and there are those in the scientific community who believe that this goal is not achievable.
One of the problems that we face as a clinical, scientific, and epidemiological community is that our early strategies for risk prediction were based on the notion that the high-risk population was a major part of the burden and that the same risk prediction parameters could be generalized from the high-risk population to the general population. The left ventricular ejection fraction (LVEF) took centrestage as a result of our focus on post-myocardial infarction patients beginning in the 1970s and continuing through the clinical trials, initially for antiarrhythmic drugs and subsequently for implantable cardioverter defibrillators (ICDs), reaching a pinnacle of reported outcomes in the late 1990s and early 2000s. 6 While LVEF continues to have a major position in our criteria of interventions such as ICDs, and has value within its limits, it clearly is not sufficient to attack the overall problem. Part of the problem derives from the strategy of dichotomizing LVEF-associated risk at 35%, rather than a gradient of risk across a broad range of values. 5, 7 In addition, the last 10 years has seen a transition from focus on the post-myocardial infarction patient, to the high-risk heart failure patient and the low-risk general population.
The large low-risk, high event number general population provides a special challenge because of the expression of SCD as first cardiac events. That phenomenon drives us to seek low-cost, easily applicable screening markers that would help identify risk with sufficient lead time to employ preventive actions efficiently. Accordingly, in recent years, one of the strategies has been to re-focus attention on markers of risk from simple clinical tools, such as clinical electrocardiography (ECG). The hypothesis that the ECG contains information that can contribute to risk prediction, while being easily accessible and analysed by computerized systems, has attracted attention.
In this issue of the journal, Aro et al. 8 report a study from the database of the Oregon Sudden Unexpected Study (SUDS) in which retrospective analysis of multiple ECG measures was applied to cardiac arrest victims to determine whether parameters from ECGs recorded prior to a cardiac arrest would provide signals to apply prospectively for predicting risk. Based upon the performance of six possible risk parameters, the investigators devised a risk score system that demonstrates an impressive SCD risk gradient between the absence of any of the markers (score = 0) and the presence of > _4 markers of risk. As a retrospective analysis tool, this scoring system performed well, providing an odds ratio of 21 between the reference group and the higher numbers of markers, expanding to 26 for the subgroup with LVEF >35%. This pattern suggests a potential for applicability to a general population, as well as added value across a gradient of LVEFs. One point of concern in this study, however, is that only 32% of the SCD victims had an ECG prior to SCD, and only As with any study of this nature, the performance of a retrospective analysis does not predict performance prospectively, especially for a more general population. In order to overcome this limitation partially, the investigators applied their ECG risk score model to the ARIC registry as a validation strategy, and identified trends in the same direction, but recorded a different distribution of scores and event numbers that were significantly lower (Figure 1 ). There are several limitations to validation using the ARIC population: one is the fact that the investigators used ARIC's baseline ECG at entry (mean age at time of ECG = 54 years) as the data source, while Oregon SUDS had access to multiple repeat ECGs in many of their subjects, and use the one closest to the cardiac arrest events (mean age 63 years). In addition, the risk factor and disease burden in the ARIC population at baseline were considerably lower than those of the Oregon SUDS population at the times of the qualifying ECGs and SCD events. Finally, ECGs were available for 86% of the subjects from ARIC, compared with the 16% available and analysed in Oregon SUDS. This combination probably contributed to the different distributions of ECG scores in the two populations (see Figure 1) .
While the signal provided by the electrical risk score in this study offers hope for applicability to a general population, its long-term predictive value will not be determined without a carefully designed prospective study of the ECG risk scoring model. I could envisage testing its usefulness in two distinct populations: the general population free of disease, with and without integration of other risk markers; and a second population consisting of patients with known cardiac disease but with a risk profile that places them in a low-risk subgroup.
This leads to thoughts about the need to take a carefully considered approach to costs and benefits of research, particularly for validation of new signals from hypothesis-generating research. 6 The notion that observing a population for a few years, as in many clinical the Oregon SUDS data extrapolated for score categories per 1000 deaths. The highest score category (4-6) was associated with 16% of the SCDs, but this subgroup had a very high odds ratio. (B) Using the 14-year median follow-up data cited from ARIC, the size of each of the five categories of ECG risk scores is provided. The data are extrapolated to score categories/1000 population for comparison purposes. The sizes of lower score categories (e.g. 0-2) are significantly larger, and very much smaller in groups 3 and 4-6. The difference in distribution between Oregon SUDS and ARIC is probably accounted for by differences in risk and disease profiles of the two populations at the time of the qualifying ECGs. (C) Extrapolating the ARIC SCD data to a population of 10 000, the distribution of SCDs in each score category, and the corresponding SCD rates, are provided. These data demonstrate that among the estimated 192 SCDs among 10 000 subjects, the increasing risk with increasing scores operates on a gradient, but the impact in terms of numbers of events per category significantly decreases between categories 1 and 4-6. This suggests that while the higher risk categories provide strong signals, the effect size is small. However, the impact would probably be increased by interactions with additional markers of risk, as suggested by comparing the two population distributions. trials, will give us sufficient outcome data to provide durable measures of risk of sufficient magnitude and effect size to impact population health is an oversimplification. An example of the need for longterm observation periods is the study from Finland on early repolarization and cardiovascular risk. 9 The investigators carried out a retrospective analysis of ECGs recorded between 1966 and 1972 as part of a population surveillance study, and looked at their population outcome over time. The interesting aspect of that study was that early repolarization identified at a relatively young age appeared to associate with mortality outcomes, but not until acquired disease during a mean follow-up of 30 years after the initial recording. The implication was that the pathophysiology behind this risk marker was useful, but only when co-existing disease emerged later in life. Moreover, subsequent refinements of their data analysis suggested that risk associated only with a specific pattern of early repolarization-horizontal/downsloping ST segments in the inferior leads.
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Another example is the four studies that looked at family history of cardiac arrest as a first cardiac event and the impact on SCD risk in family members. [11] [12] [13] [14] Each of these studies, which had very different design features, showed that the shared outcome of cardiac arrest as a first cardiac event was more common in the offspring of families when a history of cardiac arrest was historically a first cardiac event.
The feature applied to both out-of-hospital cardiac arrests and ventricular fibrillation risk during acute coronary syndromes in the various studies, and suggests the possibility of a genetic component to cardiac arrest risk.
A final point has to do with the repeated measures. The ECG, as well as many other potential pathophysiological markers, may change over time. Many population surveillance studies have used a single measure at baseline to determine the marker of risk. Repeated measures over time might identify the emergence of stronger signals, while maintaining sufficient lead times to allow risk intervention. There is a suggestion of this phenomenon from the ECG timing in Oregon SUDS and ARIC, with the differences in score distributions implying support for this hypothesis.
In summary, the electrical score signal reported in the study of Aro et al. is interesting and potentially useful. However, its relevance must be determined by prospective studies showing that it performs in a fashion similar to the retrospective analysis done in Oregon SUDS and ARIC in the general population. If so, the ECG risk score would be clinically applicable because of its ease of implementation. I anticipate that these motivated investigators, and others, will continue to validate the electrical score method, and to seek to integrate additional markers of interest, for better individual risk profiling. Hopefully, funding agencies will generate and distribute the resources required for this sorely needed research.
